Montrusco Bolton Investments Inc. Sells 102,497 Shares of Zoetis Inc. $ZTS

Key Points

• Montrusco Bolton Investments Inc. reduced its stake in Zoetis Inc. by 17.2% during the second quarter, owning 492,852 shares after selling 102,497 shares.
• Zoetis recently reported $1.76 earnings per share for the last quarter, exceeding analysts' expectations of $1.62, and had revenue of $2.46 billion.
• The company declared a quarterly dividend of $0.50 per share to be paid on December 2nd, representing an annualized dividend of $2.00 and a yield of 1.4%.

Montrusco Bolton Investments Inc. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 17.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 492,852 shares of the company's stock after selling 102,497 shares during the quarter. Zoetis accounts for about 0.9% of Montrusco Bolton Investments Inc.'s investment portfolio, making the stock its 26th largest position. Montrusco Bolton Investments Inc. owned 0.11% of Zoetis worth $76,860,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Nova Wealth Management Inc. bought a new position in shares of Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new position in shares of Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new position in shares of Zoetis during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC grew its holdings in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company's stock worth $31,000 after purchasing an additional 131 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 1.6%

ZTS stock opened at $141.05 on Monday. The company has a market cap of $62.51 billion, a P/E ratio of 24.28, a PEG ratio of 2.26 and a beta of 0.90. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $196.55. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The business has a fifty day moving average of $149.24 and a 200-day moving average of $154.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis's payout ratio is 34.42%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Weiss Ratings restated a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday, October 8th. Argus restated a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.